Global Antibody Partnering Terms and Agreements Directory 2014-2020: Q4 Updated Details of Deals by…

first_img Pinterest WhatsApp Global Antibody Partnering Terms and Agreements Directory 2014-2020: Q4 Updated Details of Deals by the World’s Leading Healthcare Companies – Previous articleTEXAS VIEW: Fort Worth schools should focus on learning, not better gradesTHE POINT: Spike in F’s demonstrates the urgent need to get students back in school.Next articleGlobal Dental Partnering Directory 2010-2020: Updated with the Latest Deal Trends, Players and Financials – Digital AIM Web Support Facebook Pinterest Local NewsBusiness Twittercenter_img TAGS  Facebook By Digital AIM Web Support – February 4, 2021 Twitter WhatsApp DUBLIN–(BUSINESS WIRE)–Feb 4, 2021– The “Global Antibody Partnering Terms and Agreements 2014-2020” report has been added to’s offering. The Global Antibody Partnering Terms and Agreements 2014 to 2020 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. This report contains over 1,600 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2014. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products. Key benefits Global Antibody Partnering Terms and Agreements 2014 to 2020 provides the reader with the following key benefits:In-depth understanding of Antibody deal trends since 2014Access to headline, upfront, milestone and royalty dataAnalysis of the structure of Antibody agreements with real life case studiesDetailed access to actual Antibody contracts enter into by the leading twenty five bigpharma companiesInsight into the terms included in a Antibody agreement, together with real world clause examplesUnderstand the key deal terms companies have agreed in previous dealsUndertake due diligence to assess suitability of your proposed deal terms for partner companies Available contracts are listed by:Company A-ZHeadline valueStage of development at signingDeal component typeSpecific therapy target Key Topics Covered: Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in antibody dealmaking 2.1. Introduction 2.2. Antibody partnering over the years 2.3. Most active antibody dealmakers 2.4. Antibody partnering by deal type 2.5. Antibody partnering by therapy area 2.6. Deal terms for antibody partnering 2.6.1 Antibody partnering headline values 2.6.2 Antibody deal upfront payments 2.6.3 Antibody deal milestone payments 2.6.4 Antibody royalty rates Chapter 3 – Leading antibody deals 3.1. Introduction 3.2. Top antibody deals by value Chapter 4 – Most active antibody dealmakers 4.1. Introduction 4.2. Most active antibody dealmakers 4.3. Most active antibody partnering company profiles Chapter 5 – Antibody contracts dealmaking directory 5.1. Introduction 5.2. Antibody contracts dealmaking directory Chapter 6 – Antibody dealmaking by technology type Chapter 7 – Partnering resource center 7.1. Online partnering 7.2. Partnering events 7.3. Further reading on dealmaking AppendicesAppendix 1 – Antibody deals by company A-ZAppendix 2 – Antibody deals by stage of developmentDiscoveryPreclinicalPhase IPhase IIPhase IIIRegulatoryMarketedFormulationAppendix 3 – Antibody deals by deal typeAsset purchaseAssignmentBigpharma outlicensingCo-developmentCollaborative R&DCo-marketCo-promotionCRADACross-licensingDevelopmentDistributionEquity purchaseEvaluationGrantJoint ventureLicensingLoanManufacturingMarketingMaterial transferOptionPromotionResearchSettlementSpin outSub-licenseSupplyTechnology transferTerminationAppendix 4 – Antibody deals by therapy areaCardiovascularCentral Nervous SystemDentalDermatologyGastrointestinalHematologyHospital careImmunologyInfectivesMetabolicMusculoskeletalObstetricsOncologyOphthalmicsOrphan diseasePediatricsPsychiatryRespiratoryAppendix 5 -Deal type definitions For more information about this report visit View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/04/2021 03:51 AM/DISC: 02/04/2021 03:51 AM

Leave a Reply

Your email address will not be published. Required fields are marked *